Weight Loss Drug Request in Pre-Diabetes

Clinical Scenario

Karen Phillips, 48, a teaching assistant, attends requesting a semaglutide (Wegovy) prescription after seeing it promoted on social media and hearing that a friend lost 3 stone on it. Her BMI is 33, HbA1c is 44 (pre-diabetes range), and she has a family history of type 2 diabetes. She has tried multiple diets over the years with short-term success followed by regain. She is frustrated with the cycle of failed dieting and sees the injection as the solution. She has not been referred to the NHS Diabetes Prevention Programme despite qualifying.

What This Case Tests

Understanding the prescribing criteria for GLP-1 receptor agonists for weight management; explaining the difference between lifestyle modification and pharmacological intervention; discussing the NHS Diabetes Prevention Programme as first-line for pre-diabetes; managing expectations about weight loss medications; addressing the emotional impact of repeated diet failure; presenting a realistic and supportive management plan

Common Mistakes Trainees Make

The three most common mistakes are: prescribing semaglutide without meeting the prescribing criteria or referring to a specialist weight management service, as GLP-1 agonists for weight management should be initiated in specialist services, not primary care; dismissing her request and simply telling her to eat less and exercise more, which ignores years of failed attempts and is demoralising; and failing to refer to the NHS Diabetes Prevention Programme, which is a NICE-recommended intervention for pre-diabetes that she has been missed for.

The Consultation Challenge

Karen is frustrated. She has spent years trying to lose weight, experiencing the demoralising cycle of initial success followed by regain. She sees semaglutide as the breakthrough that will finally work. You need to take her seriously, manage expectations, and offer a real plan.

Start by validating her frustration: 'Karen, I can hear how fed up you are with the dieting cycle, and I understand why the injection seems like the answer. Years of trying and not succeeding is exhausting, and it does not mean you have failed — it means the approach was not right for your body. I want to talk about what the evidence actually shows and what options are available.'

Explain the prescribing pathway honestly: 'Semaglutide for weight management — Wegovy — is available on the NHS, but there are specific criteria. It is prescribed through specialist weight management services, not directly by GPs. The criteria typically include a BMI of 35 or over with a weight-related comorbidity, or BMI of 30 or over with pre-diabetes in some pathways. Your BMI of 33 with pre-diabetes may qualify, but the first step would be referral to the specialist service.'

Be honest about the medication: 'I also want to be upfront about what the evidence shows. Semaglutide does produce significant weight loss — typically 10-15% of body weight. But it requires weekly injections indefinitely, has side effects including nausea and GI symptoms, and the weight tends to return when the medication is stopped. It is not a cure — it is a tool that works best alongside lifestyle changes.'

Address what has been missed: 'Something I notice is that you have not been referred to the NHS Diabetes Prevention Programme, which you absolutely qualify for with your HbA1c of 44. This is a structured programme specifically designed for people in your situation — it provides coaching, support, and a personalised plan. The evidence shows it reduces the risk of developing type 2 diabetes by 58%. I would like to refer you today.'

Present a layered plan: referral to the NHS Diabetes Prevention Programme as the immediate step, referral to the specialist weight management service to assess eligibility for pharmacological support, repeat HbA1c in 3 months, and a supportive approach that moves away from restrictive dieting toward sustainable lifestyle change.

Time check: Minutes 1-3 on validating her frustration and understanding her dieting history. Minutes 3-6 on explaining semaglutide criteria, pathway, and limitations. Minutes 6-9 on the NHS DPP referral and broader management plan. Final 3 minutes on follow-up, monitoring, and ongoing support.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you take a comprehensive weight history including previous attempts, explore the emotional impact of repeated diet failure, and identify that the NHS Diabetes Prevention Programme referral has been missed. Checking current cardiovascular risk factors alongside the pre-diabetes demonstrates thorough assessment.

Clinical Management and Medical Complexity: Examiners evaluate whether you know the prescribing pathway for GLP-1 agonists (specialist initiation, specific BMI criteria), explain the medication's benefits and limitations honestly, and refer to the NHS DPP. A layered management plan incorporating immediate lifestyle support, specialist referral, and monitoring shows comprehensive care.

Relating to Others: Examiners look for validation of her frustration without colluding with the expectation that medication alone is the answer. The ability to redirect from 'give me the injection' to 'here is a comprehensive plan' while maintaining her engagement is the key communication challenge. She should leave feeling heard and supported with a clear pathway, not dismissed or lectured.

Example Opening

Strong opening: "Hello Karen, thanks for coming in. I can see you have been thinking about this a lot. Before we talk about the injection specifically, I want to understand the full picture — tell me about your experience with weight management over the years."

When managing expectations: "I want to be honest with you about semaglutide because you deserve straight information. It does work — the evidence shows significant weight loss. But it is a weekly injection you would likely need to continue long-term, it has side effects, and the weight tends to return when you stop. It can be part of the answer, but it is not the whole answer."

Avoid: "You just need to eat less and move more" — this ignores years of failed attempts, is scientifically reductive about obesity, and will destroy the therapeutic relationship instantly.

How This Appears in the SCA

Weight loss drug requests test your knowledge of prescribing criteria, your ability to manage expectations shaped by social media, and your skill in presenting lifestyle interventions as credible alternatives. Examiners value candidates who validate the patient's frustration while directing them toward evidence-based care.

Key Statistic

The NHS Diabetes Prevention Programme reduces the risk of developing type 2 diabetes by up to 58% through lifestyle intervention. Semaglutide for weight management produces an average weight loss of 12-15% of body weight over 68 weeks, but approximately two-thirds of the weight is regained within one year of stopping the medication.

Relevant Guidelines

• NICE NG28: Type 2 diabetes prevention
• NICE TA875: Semaglutide for managing overweight and obesity
• NICE CG189: Obesity — identification, assessment and management
• NHS Diabetes Prevention Programme guidance.

Frequently Asked Questions

What are the NHS prescribing criteria for semaglutide (Wegovy) for weight management?

NICE TA875 recommends semaglutide 2.4mg for weight management in adults with a BMI of 35 or above with at least one weight-related comorbidity, or BMI of 30-34.9 with pre-diabetes (in specific pathways). It must be initiated and monitored by a specialist weight management service, not prescribed directly in primary care. Treatment should be stopped if the patient has not achieved at least 5% weight loss after 6 months. It is prescribed alongside lifestyle modifications, not as a standalone treatment.

What is the NHS Diabetes Prevention Programme and who qualifies?

The NHS DPP is a free structured programme for adults in England identified as having pre-diabetes (HbA1c 42-47 or fasting glucose 5.5-6.9). It provides personalised coaching on diet, physical activity, and behaviour change over approximately 9-12 months. Evidence shows it reduces the risk of developing type 2 diabetes by up to 58%. Referral is through the GP — Karen qualifies with her HbA1c of 44 and should have been referred when the pre-diabetes was identified. This represents a missed clinical opportunity.

How do I discuss weight management without being judgemental?

Use person-first language ('a person living with obesity' not 'an obese person'), acknowledge the complexity of weight management ('this is not about willpower — body weight is influenced by genetics, hormones, medication, sleep, stress, and environment'), validate previous efforts ('the fact that you have tried repeatedly shows determination, not failure'), and frame the plan as collaborative ('let us work out what approach would suit your life'). Avoid simplistic advice like 'eat less, move more' which ignores the biological and psychological complexity of obesity.

What are the common side effects of semaglutide for weight management?

The most common side effects are gastrointestinal: nausea (affecting up to 44% of patients), vomiting, diarrhoea, and constipation. These are usually worst during dose titration and improve over time. Less common but important side effects include gallbladder disease (including gallstones), pancreatitis (rare but serious), and injection site reactions. The dose is escalated gradually over 16-20 weeks to minimise GI side effects. Patients should be counselled about these before starting treatment.

What happens to weight when GLP-1 agonists are stopped?

Research shows that approximately two-thirds of weight lost on semaglutide is regained within 12 months of stopping the medication. This is because GLP-1 agonists work by suppressing appetite and slowing gastric emptying — effects that cease when the drug is discontinued. This is important to discuss with patients upfront: the medication is likely a long-term commitment, not a short-term fix. Lifestyle changes made during treatment may help maintain some weight loss, but the biological drive to regain weight is significant.